CDER and CBER leaders at the FDA are scheduled to meet with industry groups BIO and PhRMA to discuss the Prescription Drug User Fee Act (PDUFA) reauthorization. The talks will focus on leveraging prior knowledge to streamline the review and development of cell and gene therapy products, aiming to accelerate regulatory timelines and foster innovation in this emerging therapeutic domain.